T., Costa, E., Courville, A., Darcey, V., Fletcher, L
Discontinuation rates were substantially reduced to 16.2% (95% CI 16.0, 16.5) at 1 year and 31.0% (95% CI 30.6, 31.4) at 3 years when using a grace period of 180 days, and to 23.3% (95% CI 23.0, 23.7) at 3 years when using a grace period of 365 days
Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg)
Individuals with a BMI of 27 kg/m or greater (classified as overweight) who also have at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol
FDA-Noted Concerns: Increased heart rate Systemic vasodilatory reactions Limited clinical safety data Immunogenicity risk (antibody formation) Reported Side Effects: Injection site reactions (redness, swelling, itching) Headache Flushing Dizziness Nausea Water retention Serious Concerns: Potential for glucose metabolism disruption Theoretical cancer risk (GH/IGF-1 promote cell proliferation) Long-term safety unknown Regulatory Status United States: CJC-1295 is not FDA approved for any indication
While it is generally well-tolerated, long-term surveillance continues to monitor for potential risks
